Drugs / Everolimus
Everolimus
also known as
40-o-(2-hydroxyethyl)-rapamycin · 42-o-(2-hydroxyethyl)rapamycin · Afinitor · Afinitor disperz · Certican · RAD 666 · RAD-001 · Rapamycin, 42-o-(2-hydroxyethyl)- · +4 more
Small molecule targets FKBP1A via inhibition
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05490095 | Jul 2021 → Jan 2022 | — | Sovargen | Completed | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-01-31 | Novartis Pharmaceuticals | Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC novartis.com ↗ |
| 2016-12-16 | Novartis Pharmaceuticals | Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC novartis.com ↗ |
| 2016-06-02 | Novartis Pharmaceuticals | Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET) novartis.com ↗ |
| 2016-04-29 | Novartis Pharmaceuticals | Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors novartis.com ↗ |
| 2016-04-20 | Novartis Pharmaceuticals | Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex novartis.com ↗ |
| 2016-02-26 | Novartis Pharmaceuticals | FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET) novartis.com ↗ |
| 2015-09-27 | Novartis Pharmaceuticals | Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET novartis.com ↗ |
| 2015-05-21 | Novartis Pharmaceuticals | Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors novartis.com ↗ |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Everolimus | “Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg” NCT05490095 ↗ |
| Known as | 40-o-(2-hydroxyethyl)-rapamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | 42-o-(2-hydroxyethyl)rapamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | Afinitor | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | Afinitor disperz | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | Certican | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | RAD 666 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | RAD-001 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | Rapamycin, 42-o-(2-hydroxyethyl)- | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | SDZ-RAD | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | SVG101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05490095 ↗ |
| Known as | Votubia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Known as | Zortress | ChEMBL registry synonym — accepted as the source's own label CHEMBL1908360 ↗ |
| Action | Inhibit | “FK506-binding protein 1A inhibitor” CHEMBL1908360 ↗ |
| Modality | Small molecule | — CHEMBL1908360 ↗ |
| Route | Oral | “after oral administration of SVG101 (dispersible tablet of everolimus) 5mg” NCT05490095 ↗ |
| Target | FKBP1A | “FK506-binding protein 1A inhibitor” CHEMBL1908360 ↗ |